Overview
Dr. Vajzovic is a vitreoretinal surgeon and tenured Professor of Ophthalmology at Duke University School of Medicine with expertise in adult and pediatric retinal diseases and surgery.
Dr. Vajzovic is passionate about translational research and collaborates closely with Duke biomedical engineers to develop imaging devices to improve ophthalmic care. She serves as a principal investigator for numerous national clinical trials in early to late stages of development. Her research interests span from pediatric retinal diseases such as retinopathy of prematurity to adult diseases such as age-related macular degeneration, diabetic retinopathy and venous occlusive diseases, as well as vitreoretinal surgical topics such as retinal tears, retinal detachments, macular holes and macular puckers.
In addition, Dr. Vajzovic is interested in cutting edge technologies and recovery of vision in hereditary and common retinal diseases with gene-therapy, stem cell technology and retinal implants. She is a co-director of the Duke Pediatric Retina and Optic Nerve Center, and directs the Duke Center for Artificial and Regenerative Vision, where she performs gene-therapy delivery, and implantation of the Argus II “bionic eye” to restore vision to individuals with total blindness.
An influential educator, she organizes and directs several highly successful national and international courses, including the first-of-its-kind Advances in Pediatric Retina Course at Duke and the international Duke Fellows Advances in Vitreous Surgery Course. She is director of prestigious Duke Vitreoretinal Surgical Fellowship and director of Duke Eye Center’s Continuing Medical Education program.
Dr. Vajzovic completed her vitreoretinal fellowship training at Duke and residency training at Bascom Palmer Eye Institute in Miami, FL. While in training, she received Heed Fellowship Award, Society of Heed Fellows Award and Retina Society Research Award. She is active on the Women in Ophthalmology Board of Directors where she serves as a Treasurer and a Chair of Clinical Trial Training Program. In addition, she serves as a Retina Society AAO Council Representative. She is elected member of the Retina Society, Macula Society and Club Jules Gonin Society. Dr. Vajzovic has been awarded the American Academy of Ophthalmology Achievement Award, American Society of Retina Specialists Senior Honor Award, Women in Ophthalmology Emerging Leader Award and Emerging Leader Award by Duke University School of Medicine and Duke Medical Alumni Association.
Current Appointments & Affiliations
Recent Publications
Effect of Faricimab on Visual Acuity and Retinal Structure in Neovascular Age-Related Macular Degeneration Previously Treated With Anti-VEGF Therapy.
Journal Article J Vitreoretin Dis · August 30, 2025 Purpose: To evaluate the effects of switching from traditional antivascular endothelial growth factor (anti-VEGF) therapies to faricimab, a biclonal antibody that targets both VEGF and angiopoietin-2, on eyes with neovascular age-related macular degenerati ... Full text Link to item CitePegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE.
Journal Article Am J Ophthalmol · August 2025 PURPOSE: To report 12-month results from the GALE open-label extension study (NCT04770545), evaluating up to 36 months of intravitreal pegcetacoplan treatment for geographic atrophy (GA) in age-related macular degeneration (AMD). DESIGN: GALE is a prospect ... Full text Link to item CiteCoring of Intravitreal Medication Vial Stoppers: A Report From the Research in Safety and Therapeutics Committee of the American Society of Retina Specialists.
Journal Article J Vitreoretin Dis · July 14, 2025 In 2024, the American Society of Retina Specialists (ASRS) Research and Safety in Therapeutics (ReST) Committee became aware of reports of coring of vial stoppers in relation to preparation of intravitreal injections. A literature review was performed to f ... Full text Link to item CiteRecent Grants
A Multi-Center, Randomized, Double-Masked, Active-Comparator-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Ixoberogene soroparvovec (Ixo-vec) in Participants with Neovascular Age-Related Macular Degeneration (ARTEMIS)
Clinical TrialPrincipal Investigator · Awarded by Adverum Biotechnologies, Inc · 2025 - 2030A Phase 3, Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age- Related Macular Degeneration
Clinical TrialPrincipal Investigator · Awarded by Ocular Therapeutix Inc · 2025 - 2030A Randomized, Open-Label, Parallel-group, Multicenter Phase 1/2 Study to Evaluate the Safety and Exploratory Efficacy of NT-101 Topical Ophthalmic Solution in Patients with Wet Age-Related Macular Degeneration (AMD)
Clinical TrialPrincipal Investigator · Awarded by NexThera Co., Ltd. · 2025 - 2030View All Grants